Author

D. Kaymak

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Assay:bulk RNA-seq· 2 Research Focus:cancer & tumor microenvironment· 2 Organism:mouse· 2 Assay:proteomics· 2 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Research Focus:differential expression· 1

Frequent Co-Authors

M.-F. Ritz· 3 shared P. Schmassmann· 3 shared S. Hogan· 3 shared T. A. Martins· 3 shared T. Shekarian· 3 shared A. Buck· 2 shared A. Gerber· 2 shared B. Snijder· 2 shared

Activity by Year

2022-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

M.-F. Ritz

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Enhancing anti-EGFRvIII CAR T cell therapy against glioblastoma with a paracrine SIRPγ-derived CD47 blocker

T. A. Martins, N. Tatari, D. Kaymak, S. Hogan, E. M. Bartoszek, R. Wieboldt, M.-F. Ritz, A. Buck, M. McDaid, A. Gerber, A. Beshirova, M. M. Etter, A. Heider, T. Shekarian, H. Mohamed, , G. Hutter

This paper develops a CAR T cell therapy that secretes a CD47 blocker to enhance anti-EGFRvIII efficacy against glioblastoma by modulating the tumor microenvironment.

bioRxiv · Aug 31, 2023Cancer Biology

Multidimensional analysis of matched primary and recurrent glioblastoma identifies Fcgamma receptors upregulation on microglia as a contributor of tumor recurrence.

T. Shekarian, S. Hogan, T. A. Martins, P. Schmassmann, A. Gerber, J. Roux, D. Kaymak, C. Durano, B. Burger, M. Matter, M.-F. Ritz, G. A. Hutter

This study identifies Fcgamma receptor upregulation on activated microglia in recurrent glioblastoma as a factor associated with shorter time-to-relapse.

bioRxiv · Apr 21, 2023 · PreprintCancer Biology

The Siglec-sialic acid-axis is a target for innate immunotherapy of glioblastoma

P. Schmassmann, J. Roux, A. Buck, N. Tatari, S. Hogan, J. Wang, S. Lee, B. Snijder, T. A. Martins, M.-F. Ritz, T. Shekarian, D. Kaymak, M. McDaid, M. Weller, T. Weiss, , G. Hutter

This study identifies the Siglec-sialic acid-axis as a target for innate immunotherapy in glioblastoma, showing that blocking Siglec-E enhances phagocytosis and T cell priming, leading to delayed tumor growth and prolonged survival.

bioRxiv · Nov 7, 2022Cancer Biology